Sorbonne University

Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer

Retrieved on: 
Vendredi, juin 30, 2023
Molecular mimicry, CDC20, CRC, Microsatellite instability, Non-Hodgkin lymphoma, Immune tolerance, Adrenal tumor, Research, Immunotherapy, Glioblastoma, Assistant, Oncology, Colorectal cancer, Service provider, AP-HP, CD8, FOXM1, Patient, Cancer, Epitope, Neoplasm, Sorbonne University, Nivolumab, Safety, UCP2, Peptide, Inflammation, Vaccine, Pharmaceutical industry, Medical imaging, UBE2C

These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the tumor-associated antigens (TAAs) BIRC5/survivin, FOXM1, UBE2C, CDC20 and KIF2C.

Key Points: 
  • These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the tumor-associated antigens (TAAs) BIRC5/survivin, FOXM1, UBE2C, CDC20 and KIF2C.
  • EO4010 also includes universal cancer peptide 2 (UCP2), a helper peptide representing the CD4+ epitope.
  • The Company is also initiating a Phase 2 clinical study in patients with ctDNA-defined, Minimal Residual Disease of colorectal cancer, with its fourth candidate EO2040.
  • This groundbreaking approach so far demonstrates both efficacy and safety for the patients, instilling real hope in the fight against cancer.”

GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

Retrieved on: 
Mardi, mai 23, 2023
University, NASH, Hepatology, Biomarker, Journal, Patient, Physician, Data, Conformity, IVD, Diagnosis, Entrepreneurship, Sorbonne University, University of Oxford, Medical imaging, Medical device, Euronext

It is a non-invasive diagnostic technology designed as an optimization of NIS4® technology, a blood-based panel currently used to detect at-risk NASH.

Key Points: 
  • It is a non-invasive diagnostic technology designed as an optimization of NIS4® technology, a blood-based panel currently used to detect at-risk NASH.
  • In November 2021, NIS4® was recognized by the NIMBLE2 Initiative of the FNIH’s3 Biomarkers Consortium as showing a unique performance in identifying patients with at-risk NASH.
  • Data presented at the AASLD4 Liver Meeting® in October 2022 demonstrated the robust and improved clinical performance of NIS2+™ allowing an efficient identification of at-risk NASH, irrespective of patient characteristics such as age, sex and type 2 diabetes.
  • NIS2+™ is the only blood-based technology developed for the identification of at-risk NASH allowing it to be applied for large-scale use in clinical practice.

MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting

Retrieved on: 
Mardi, avril 11, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EBMT, Failure, Survival, Cancer, Maat, Microbiota, Transplant, Capsule, ARES, Patient, American Society of Hematology, Gut microbiota, Host, MET, Hospital, European Society for Primary Immunodeficiencies, Congress, Special access program, Sorbonne University, Society, ORR, Pharmaceutical industry, Birth control, Hematology

The EBMT Annual Meeting is a leading event in Europe that focuses on cutting-edge scientific content related to transplantation and cellular therapy.

Key Points: 
  • The EBMT Annual Meeting is a leading event in Europe that focuses on cutting-edge scientific content related to transplantation and cellular therapy.
  • The oral presentations will include data that were previously presented at the American Society of Hematology conference in December 2022.
  • - MaaT Pharma is preparing a randomized, double-blind, placebo-controlled pivotal Phase 2b clinical trial for MaaT033; trial start is expected in Q2 2023 as previously announced.
  • All EBMT sessions that take place onsite will be live-streamed through the congress platform and will be available on-demand after they are aired live.

ENNISMORE ANNOUNCES MONDRIAN ABU DHABI - THE BRAND'S FIRST LOCATION IN THE UAE, OPENING IN 2024

Retrieved on: 
Lundi, mars 20, 2023
Heart, DNA, Food, DNA Lounge, ABU, Sorbonne University Abu Dhabi, Abu Dhabi Mall, Restaurant, Sorbonne University, United Arab Emirates, Corniche, Hotel, Amusement park, Piet Mondrian, Ennismore

ABU DHABI, UAE, March 20, 2023 /PRNewswire/ -- Ennismore, the fastest-growing lifestyle hospitality company, today announces it will open Mondrian Abu Dhabi, the brand's first project in the United Arab Emirates, in collaboration with Al Hazoom Group. Opening in 2024 and located in the city's bustling downtown area alongside the Abu Dhabi canal, Mondrian Abu Dhabi will be a spectacular hotel providing waterfront views overlooking both Reem Island and Maryah Island and direct views of the city skyline. The project has already broken ground and will join the Mondrian portfolio of seven operating hotels.

Key Points: 
  • ABU DHABI, UAE, March 20, 2023 /PRNewswire/ -- Ennismore, the fastest-growing lifestyle hospitality company, today announces it will open Mondrian Abu Dhabi, the brand's first project in the United Arab Emirates, in collaboration with Al Hazoom Group.
  • Opening in 2024 and located in the city's bustling downtown area alongside the Abu Dhabi canal, Mondrian Abu Dhabi will be a spectacular hotel providing waterfront views overlooking both Reem Island and Maryah Island and direct views of the city skyline.
  • Mondrian Abu Dhabi will offer a chic crystal-clear lagoon where guests can enjoy a beverage while soaking in the sun.
  • Designed by award-winning interior architect Tristan Du Plessis, Mondrian Abu Dhabi will be as fantastical as it is timelessly imaginative and inviting.

Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer

Retrieved on: 
Mardi, mars 14, 2023
Bladder cancer, University, Arunachal University of Studies, Congress, Knowledge, EAU, BLC, White Light, Tumor microenvironment, Recurrence, Risk, Name, European Association of Urology, Sorbonne University, HAL, Patient, WLC, ClinicalTrials.gov, Calendar, Division, Health, APHP, TURBT, Aarhus University Hospital, Cystoscopy, Urology

OSLO, Norway, March 14, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the European Association of Urology congress (EAU) in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.

Key Points: 
  • OSLO, Norway, March 14, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the European Association of Urology congress (EAU) in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.
  • This year's event was held on March 10 -13, 2023 and attracted urologists from all over the world.
  • In addition to an active presence & support for the event, Photocure will also be making bladder cancer session highlights available post event by means of video interviews with the presenters of these sessions.
  • "These new study results continue to emphasize the importance of performing a thorough TURBT using Blue Light Cystoscopy in the treatment of bladder cancer, and also demonstrate the strong interest from the scientific community to investigate Hexvix®/Cysview's potential immunologic effects in bladder cancer management.

Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer

Retrieved on: 
Mardi, mars 14, 2023
Bladder cancer, University, Arunachal University of Studies, Congress, Knowledge, EAU, BLC, White Light, Tumor microenvironment, Recurrence, Risk, Name, European Association of Urology, Sorbonne University, HAL, Patient, WLC, ClinicalTrials.gov, Calendar, Division, Health, APHP, TURBT, Aarhus University Hospital, Cystoscopy, Urology

OSLO, Norway, March 14, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the European Association of Urology congress (EAU) in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.

Key Points: 
  • OSLO, Norway, March 14, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the European Association of Urology congress (EAU) in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.
  • This year's event was held on March 10 -13, 2023 and attracted urologists from all over the world.
  • In addition to an active presence & support for the event, Photocure will also be making bladder cancer session highlights available post event by means of video interviews with the presenters of these sessions.
  • "These new study results continue to emphasize the importance of performing a thorough TURBT using Blue Light Cystoscopy in the treatment of bladder cancer, and also demonstrate the strong interest from the scientific community to investigate Hexvix®/Cysview's potential immunologic effects in bladder cancer management.

MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth

Retrieved on: 
Lundi, mars 6, 2023
CEF, Regenerative medicine, Accenture, Lifecell, Telecommunications, Acquisition, University of Michigan, LATAM, Franklin & Marshall College, Growth, Strategy, Business administration, Regeneration, European Operations Management Association, Paris 1 Panthéon-Sorbonne University, Surgeon, Marshall College, Sorbonne University, Corporate development, Veteran, Breast cancer, University, Bristol Myers Squibb, Triple accreditation, Master of Business Administration, Inflammation, Marketing, Small Business Saturday, MS, Management, Fine chemical, Economics, Coloplast

YAVNE, Israel, March 06, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the appointment of Barry Wolfenson as Executive Vice President of Strategy & Corporate Development. In this role, Mr. Wolfenson will be responsible for the Company’s global strategic plan, business development and initiatives to generate overall growth. MediWound also announced the appointment of Alicia Torrenova, as Vice President of European Operations.

Key Points: 
  • In this role, Mr. Wolfenson will be responsible for the Company’s global strategic plan, business development and initiatives to generate overall growth.
  • “We are very pleased to welcome Barry and Alicia to the MediWound team.
  • Both are seasoned veterans with over 20 years of relevant experience, including having held leadership roles in strategy planning, business and corporate development,” said Ofer Gonen, Chief Executive Officer of MediWound.
  • Mr. Wolfenson said, “I am excited to join the MediWound management team and be part of its exciting journey.

ALD announces General Management committee change

Retrieved on: 
Dimanche, décembre 18, 2022
Acquisition, Executive, Regulatory News Service, ALD, Compartment (heraldry), Heart, Sorbonne University, ALD Automotive, ISIN, Operation, LeasePlan, Growth, Ticker, Rale, SME, International trade, Paris Dauphine University, Security (finance), Management, Euronext Paris

ALD today announces that Gilles Bellemère has decided to step down from his position as Deputy Chief Executive Officer of ALD, effective 31 December 2022, in order to focus on his role as Chief Executive Officer of ALD Automotive France, the Group’s largest subsidiary, in addition to the direct supervision of ALD Automotive in Morocco and Algeria.

Key Points: 
  • ALD today announces that Gilles Bellemère has decided to step down from his position as Deputy Chief Executive Officer of ALD, effective 31 December 2022, in order to focus on his role as Chief Executive Officer of ALD Automotive France, the Group’s largest subsidiary, in addition to the direct supervision of ALD Automotive in Morocco and Algeria.
  • This decision to adapt the organisation of the Group’s General Management team was approved by ALD’s Board of Directors.
  • In addition to his role as Deputy Chief Executive Officer of ALD, Gilles Bellemère, was appointed Chief Executive Officer of ALD Automotive France in 2019.
  • ALD is listed on Compartment A of Euronext Paris (ISIN: FR0013258662; Ticker: ALD).

MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting

Retrieved on: 
Dimanche, décembre 11, 2022
Research, Hospitals, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Maintenance, Haematopoietic system, Prognosis, Hematopoietic stem cell transplantation, Sorbonne University, Infection, Poster, Microbiota, Biomarker, Patient, Șaeș, Cancer, Graft-versus-host disease, Capsule, MET, Acute leukemia, Survival, Lymphatic system, AML, Safety, Hospital, Mortality, Acute myeloid leukemia, ASH, Euronext Paris, CGMP, Risk, Pharmaceutical industry, Dietary supplement, Medical imaging

MaaT Pharmas mission is to improve cancer patients lives by driving innovation in the microbiome therapeutics field, said Herv Affagard, CEO and co-founder of MaaT Pharma.

Key Points: 
  • MaaT Pharmas mission is to improve cancer patients lives by driving innovation in the microbiome therapeutics field, said Herv Affagard, CEO and co-founder of MaaT Pharma.
  • These positive Phase 1b results reinforces the strong potential for our MET oral formulation, MaaT033, and we plan to investigate it as an adjunctive and maintenance treatment in patients with hematological malignancies.
  • Prof. Mohamad Mohty added, Allo-HSCT is often the only curative approach for patients with hematological malignancies such as acute leukemia.
  • In the dose-finding Phase 1b CIMON trial, 21 patients with acute myeloid leukemia (AML) were treated with MaaT033 and evaluated for safety, tolerability, and initial signs of microbial species engraftment.

MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting

Retrieved on: 
Samedi, décembre 10, 2022
Research, Infectious Diseases, Hospitals, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Phase, Infection, Immune system, GI, ORR, Food, Sorbonne University, Acceleration, Skin, ARES, Orphan, EMA, Patient, Cancer, Steroid, Graft-versus-host disease, MET, DSMB, Liver, FDA, Classification, US Foods, Survival, Biomarker, Authorization, European Medicines Agency, MAGIC, Clinical trial, ANSM, Safety, Hospital, Degenerative disease, Mortality, Euronext Paris, EAP, ASH, CGMP, CST, Pharmaceutical industry, Dietary supplement

In patients responding to MaaT013 therapy, the overall survival (OS) rate at 12 months was 59% (compared to 14% for non-responders) indicating a significant clinical benefit with MaaT013.

Key Points: 
  • In patients responding to MaaT013 therapy, the overall survival (OS) rate at 12 months was 59% (compared to 14% for non-responders) indicating a significant clinical benefit with MaaT013.
  • This patient population resembles the ongoing Phase 3 ARES clinical trial ( NCT04769895 ) being conducted in Europe.
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.
  • MaaT Pharma is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).